Introduction of medical products into healthcare practice and costs reimbursement: European experience
Author(s) -
V. V. Omelyanovsky,
Stanislav S Otstavnov,
Н. З. Мусина,
V. S. Dombrovskii
Publication year - 2018
Publication title -
farmakoekonomika modern pharmacoeconomics and pharmacoepidemiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.177
H-Index - 3
eISSN - 2070-4933
pISSN - 2070-4909
DOI - 10.17749/2070-4909.2018.11.2.059-066
Subject(s) - reimbursement , transparency (behavior) , health care , european union , russian federation , business , medical practice , health technology , medicine , political science , medical education , international trade , economic policy , law
in the present article, we review the ways of introducing medical products into healthcare practice in countries of the european Union and compare them with the Russian experience. in this analysis, we underscore the existing differences but also identify the common aspects, for example, the mandatory stage of integrated assessment; all those are described in detail in the review. The eU experience should be considered when introducing medical products into the healthcare practice in the Russian Federation. The comprehensive assessment of new technologies will provide for the transparency of the proposed system.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom